Inbios International Inc.

Inbios International Inc., a minority-owned, Subcontinent Asian American–owned for-profit biotechnology manufacturer based in Seattle, Washington, designs, develops, and manufactures immunodiagnostic devices and rapid diagnostic tests for infectious diseases, selling primarily to federal health and defense agencies as a prime contractor (99% of recent awards) under open competition and small-business set-asides. The company holds a $148 million CDC multiple-award Indefinite Delivery Contract awarded in September 2025 for diagnostic testing capabilities, along with a substantial footprint of definitive contracts and purchase orders across the Department of Health and Human Services, Department of Defense, and civilian agencies.

Inbios's recent award portfolio is dominated by CDC and Army medical procurement. The top five customer agencies account for 73% of recent award count and 95% of combined potential value, anchored by CDC Pittsburgh (24 awards, $148.7 million combined potential value) and Army Medical Command (21 awards, $65.4 million combined potential value), with the Army's Joint Program Executive Office for Chemical and Biological Defense contributing an additional $52 million for COVID-19 over-the-counter test kits. The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response accounts for $43.9 million across five awards, largely for COVID-19 test procurement during 2022–2023. Capability work spans rapid diagnostic tests for Chagas disease, Ebola virus disease, prostate-specific antigen, and visceral leishmaniasis reagent kits, along with COVID-19 rapid tests in both over-the-counter and government-procured forms. The company also holds a Phase II SBIR contract with the National Cancer Institute valued at $454,183 for development of a rapid at-home prostate-specific antigen test using self-collected finger stick blood, completed in September 2025.

Award activity contracted sharply after 2022. The company received seven awards in 2022 (driven by $52 million Army COVID kit procurement and related Defense Logistics Agency and CDC purchases), two in 2023, four in 2024, one in 2025, and two in 2026 to date. Combined potential value across all 97 awards (prime and sub) is $353 million, with $158 million obligated (45% of potential value). Only two awards carry ultimate completion dates within the next twenty-four months, with combined potential value of $12.1 million, presenting limited near-term recompete exposure. The vendor operates almost exclusively as a prime (99% of awards); one grant sub-award recorded as of the source date is an NSF Convergence Accelerator sub-grant from the Board of Regents of Nevada System of Higher Education, focused on quantum-dot sensor technology for disease detection during fiscal year 2027.

On SCI-reportable federal service contracts (contracts above the $150,000 reporting threshold), Inbios invoiced $295 thousand across FY2024 alone; the dataset shows minimal service-contract activity in other years, likely reflecting that the vendor's primary federal revenue derives from product sales (diagnostic kits, reagents, tests) and definitive contracts rather than time-and-materials or labor-hour service engagements. When SCI data is present, government-paid median hourly rates ran around $121.80 per hour, with the 10th percentile at $111.52 per hour and 90th percentile at $132.08 per hour. The vendor does not engage subcontractors on SCI-reportable prime contracts; delivery is built from internal capability. The company's award footprint centers on NAICS In-Vitro Diagnostic Substance Manufacturing (36 awards) and Research and Development in Biotechnology (10 awards), with PSC activity split among Laboratory Equipment and Supplies (32 awards) and In Vitro Diagnostic Substances, Reagents, Test Kits and Sets (18 awards). Federal grant awards from the National Institute of Allergy and Infectious Diseases fund development of next-generation Chagas DetectTM Plus rapid test technology, with Phase II grant performance running through April 2027.

InBios develops and manufactures in-vitro diagnostic tests for human and veterinary use. The company also performs assay development and contract manufacturing